Exclusive nuclear IGF1R correlated with a better outcome in sarcoma patients treated with an IGF1R mAb (Asmane et al., 2012), indicating that nuclear staining in the absence of cytoplasmic IGF1R may be a useful biomarker; however, this study had small numbers of patients. Here, IGF1R is linked to sarcoma.